Molecular clocks control mutation rate in human cells
Cancer and ageing could be predetermined by the speed of molecular clocks
Every cell in the human body contains a copy of the human genome. Through the course of a lifetime all cells are thought to acquire mutations in their genomes. Some of the mutational processes generating these mutations do so in bursts and these will often be through external exposures such as sunbathing or tobacco smoking. Other mutational processes, however, may be internal to the cell and generate mutations continuously, at a constant rate over decades. If so the mutations they generate will be “clock-like”, with the number of mutations present correlating with the age of the person. In research reported in Nature Genetics two clock-like mutational processes have been found in human cells and the rates at which the two clocks tick in different human cell types have been determined.
These clock-like mutational processes could ultimately be responsible for a large proportion of human cancer and contribute to human ageing.
The genomes of cancer cells held the key to finding these molecular clocks. Previous work on cancer had revealed that mutations often leave a molecular fingerprint, called a mutational signature, on the genome of a cancer cell. To identify the mutational signatures of clock-like mutational processes in the human body, this study looked at the DNA sequences of 10,250 cancer genomes, from 36 different types of cancer.
The researchers found 33 mutational signatures in the cancer genomes, but only two had clock-like features. These two clock-like processes, termed Signature 1 and Signature 5, showed a correlation between the number of mutations found in each cancer sample and the age of the patient when the cancer was diagnosed.
“This is a hugely exciting finding as it solves a longstanding question. Not only has this study proved that mutational molecular clocks exist, it has also shown that there are two separate clock processes that are constantly degrading DNA. How fast these clocks tick in a cell may well determine both the ageing of this cell and the likelihood for it to become cancerous.”
Dr Ludmil Alexandrov Corresponding author and Oppenheimer Fellow at Los Alamos National Laboratory in the USA
The molecular clocks generate mutations at a steady rate, the ‘ticking’ rate of the clock, and accumulate more mutations with age. By investigating 7,329,860 somatic mutations from the cancer genomes, the researchers were able to effectively look back in time, calculating which mutations each cell had had before it became a cancer cell. This showed them how fast the mutational clocks had generated the mutations. This information could help researchers understand the biology of cancer development and even look at the rate that primary cancer cells spread to other parts of the body (metastasis).
“This study is important and could have practical implications for cancer patients. In the future it could lead to clinicians being able to compare the genomes of a primary tumour and any metastases, and determine the length of time it had taken to spread. Because the clock continues to tick in the cancer, it may also be possible to help doctors predict for new patients how quickly a cancer may change, for example to become metastatic to other parts of the body or to acquire resistance to a drug. This could help doctors plan the best course of treatment for a patient.”
Dr Julian Sale An author on the paper and group leader at the MRC Laboratory of Molecular Biology
Both Signature 1 and Signature 5 clock-like processes accumulated mutations at a constant rate over time and operate in essentially all cell types in the human body. However they exhibited substantially different mutation rates in the different tumour types and surprisingly they also had different rates to each other, even in the same type of tumour. The fact that they behave differently indicates that they are likely to be due to two different biological processes.
The mutation rate of Signature 1 was highest in cells with high turnover rates, such as stomach and colorectal cells, and appeared to be due to certain methylated cytosine bases transforming into thymine, leading to mismatches in the genome which are converted into mutations when a cell divides. The mutational process for Signature 5 is mysterious. However, unlike Signature 1, the Signature 5 mutation rate did not correlate with the number of cell divisions. More research is needed on both these processes to understand their full roles in the cell.
“This is the first identification and quantification of mutational molecular clocks, and was carried out by looking through the “cracked lens” of cancer genomes. Over the next few years, we hope to perform large-scale sequencing directly of all types of normal cells to refine these clock-like mutation rates. In addition, further research is particularly needed to understand the nature of the mutational processes generating these clock-like mutations.”
Professor Sir Michael Stratton Corresponding author and Director of the Wellcome Trust Sanger Institute
Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Los Alamos National Security, LLC, a team composed of Bechtel National, the University of California, BWX Technologies, Inc. and URS Corporation for the Department of Energy’s National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health and global security concerns.
The Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) is one of the world’s leading research institutes. Discoveries and inventions developed at the LMB, for example DNA sequencing and methods to determine the structure of proteins, have revolutionised all areas of biology. Its scientists work to advance understanding of biological processes at the molecular level. This information will help us to understand the workings of complex systems, such as the immune system and the brain, and solve key problems in human health.
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
14 Feb 2024
Key genes linked to DNA damage and human disease uncovered
Scientists unveil 145 genes vital for genome health, and possible strategies to curb progression of human genomic disorders
25 Jan 2024
Leading UK and South African genomics labs unite to take disease surveillance beyond COVID
Building on genomic surveillance success during the pandemic, this close collaboration will track more pathogens in more places